Who is moving to which position
Resolved 24 June 2026Incoming appointee
4 itemsDeparting officer
2 items“Next role stated” means the document names the position the person holds after stepping down. It does not necessarily mean they are leaving the company.
Christophe Weber: not disclosed. 6 Outside Directors: not disclosed
Christophe Weber retired from the Board of Directors. The 6 Outside Directors also retired.
The election of new directors at the 150th Annual General Meeting of Shareholders and the determination of directors’ responsibilities and related matters by the Board of Directors and Audit & Supervisory Committee following the meeting.
Bruce Broussard: In addition to extensive experience as a top executive of large global companies, he has deep knowledge of international management and the U.S. healthcare sector., Kimura Koichiro (木村 浩一郎): As former Representative of the PwC Japan Group, he has extensive experience in geopolitical risks and corporate governance in the Asia-Pacific region., Dr. Paul Stoffels: As Chief Scientific Officer (CSO) of Johnson & Johnson and CEO of Galapagos, he led the global launches of 25 pharmaceutical products and has outstanding experience in pharmaceutical research and development.
| Item | Details |
|---|---|
| Resolution date | 24 June 2026 |
| Scheduled Appointment Date | 24 June 2026 (appointment following shareholder approval at the 150th Annual General Meeting of Shareholders and a resolution by the Board of Directors thereafter) |
| Date of departure | 24 June 2026 (at the conclusion of the 150th Annual General Meeting of Shareholders) |
| Name of appointee | Julie Kim, Bruce Broussard, Kimura Koichiro (木村 浩一郎), Paul Stoffels |
| Appointee's new position | Representative Director, President and CEO, Outside Director, Audit and Supervisory Committee Member, Outside Director and Chair of the Audit & Supervisory Committee, Outside Director (substitute director who is an Audit & Supervisory Committee Member) |
| Appointee's previous position | Director and CEO of Takeda Pharmaceuticals U.S.A., Inc. (current), Not disclosed, Former Representative of the PwC Japan Group, Chief Scientific Officer (CSO) of Johnson & Johnson and CEO of Galapagos |
| Appointee's date of birth | Julie Kim: 6 June 1970. Others: not disclosed |
| Year the appointee joined the Company | Julie Kim: 2019. Others: not disclosed |
| Number of shares held by the appointee | Julie Kim: 173,773 ADS (as of the date of this report, she does not own the Company’s common shares). Others: not disclosed |
| Name of departing officer | Christophe Weber, 6 Outside Directors (names not identified in the main text) |
| Former position of departing officer | Representative Director, President and CEO, Outside directors |
| New position of departing officer | Retired from the Company and its Board of Directors, Retirement |
| Reason for departure | Christophe Weber: not disclosed. 6 Outside Directors: not disclosed |
| Whether the incumbent will remain in office | Christophe Weber retired from the Board of Directors. The 6 Outside Directors also retired. |
| Reason for change | The election of new directors at the 150th Annual General Meeting of Shareholders and the determination of directors’ responsibilities and related matters by the Board of Directors and Audit & Supervisory Committee following the meeting. |
| Reasons for appointment | Bruce Broussard: In addition to extensive experience as a top executive of large global companies, he has deep knowledge of international management and the U.S. healthcare sector., Kimura Koichiro (木村 浩一郎): As former Representative of the PwC Japan Group, he has extensive experience in geopolitical risks and corporate governance in the Asia-Pacific region., Dr. Paul Stoffels: As Chief Scientific Officer (CSO) of Johnson & Johnson and CEO of Galapagos, he led the global launches of 25 pharmaceutical products and has outstanding experience in pharmaceutical research and development. |
| Number of directors after the change | 11 directors, including 8 outside directors |
| Subject to Approval by the General Meeting of Shareholders | Yes. Approval of the election of directors at the 150th Annual General Meeting of Shareholders, to be held on 24 June 2026. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To complete the 18-month CEO transition process. To drive contributions to patients, sustainable profit growth, the launch of multiple new products, and pipeline advancement in pursuit of new growth.